657 results about "Ribose" patented technology

Provided herein are methods of treatment comprising administering a selective ribonucleotide reductase (RNR) inhibitor in combination with other therapeutic agents, thereby treating cancer and preventing or reversing resistance to the therapeutic agents.

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.

The invention discloses application of a ganoderma lucidum strain SS30 in preparation of a product for treating cancers, and belongs to the technical field of biology. The invention provides ganoderma lucidum strain SS30 mycelium polysaccharide. The ganoderma lucidum strain SS30 mycelium polysaccharide is prepared from glucose, galactose, mannose, fucose, xylose, arabinose, rhamnose, glucuronic acid, glucosamine, ribose and lacturonic acid. The polysaccharide has a remarkable effect of inhibiting transplantable pancreatic cancer and primary colorectal cancer, can achieve the effect of treating cancer by improving the immune function and reducing the oxidation product generation level, provides a new material for development and utilization of lucid ganoderma and products thereof, and has a wide application prospect. And a research basis is provided for research and development of cancer-related drugs and research of a cancer treatment mechanism.

The invention relates to the field of establishment of fingerprints of traditional Chinese medicinal materials, in particular to an establishment method and application of a salvia miltiorrhiza polysaccharide HPLC (High Performance Liquid Chromatography) fingerprint. The establishment method comprises the following steps: preparation of a test solution: taking a salvia miltiorrhiza polysaccharide hydrolysis solution, carrying out derivatization in a reaction bottle, and passing through a 0.1-0.3 [mu] m microporous filter membrane; preparing a reference substance solution, namely weighing mannose, ribose, rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose reference substances, and preparing into a mixed reference substance solution; performing HPLC (high performance liquid chromatography) determination; and establishing the salvia miltiorrhiza polysaccharide HPLC fingerprint spectrum. According to the method, the difference of monosaccharide composition and content in salvia miltiorrhiza medicinal materials from different producing areas and the spectrum-effect relationship between antioxidant activity and anticoagulant activity are clarified, and a certain reference basis is provided for quality control and evaluation of the salvia miltiorrhiza medicinal materials from the aspect of polysaccharide.

Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I):or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, R4, R5, L, L1, L2, L3, L4, M, q, w and n are as defined herein. Methods associated with preparation and use of such compounds is also provided.

Provided in the present disclosure are certain compounds for inhibiting the activity of Poly ADP-Ribose Glycohydrolase (PARG). The present disclosure also relates to a method for preparing these compounds, a pharmaceutical composition comprising same, and the use thereof in the treatment of cancers and other diseases. The compounds have the structure as shown in formula (IA).

A method for training a deep learning model configured for virtual screening of molecules for micro ribonucleic acid (miRNA) drug discovery includes creating a training dataset including a plurality of assay datasets. The method also includes training the deep learning model to learn a plurality of tasks; performing, using the deep learning model, inference for the respective task associated with at least one miRNA assay dataset; and evaluating respective performance metrics associated with the respective predictions for each of the plurality of tasks. The method further includes selecting a set of the plurality of assay datasets for training; and training the deep learning model to learn a set of the plurality of tasks using the set of the plurality of assay datasets. The trained deep learning model is configured to predict molecules capable of affecting a target miRNA.

The invention provides a shikimic acid pathway artificial operon and a construction method and application thereof.According to the artificial operon, shikimic acid pathway related genes are integrated and connected in different modes, a trc promoter and an RBS ribose binding site sequence are optimized, and the artificial operon formed through combination has the advantages of being stable, efficient and wide in applicability; different from a relatively extensive shikimic acid way transformation mode in the past, the operon can obviously improve the accumulation capacity of aromatic amino acid, and when the operon is applied to an L-phenylalanine production strain, the yield of L-phenylalanine reaches 105 g / L, and the saccharic acid conversion rate reaches 26.5%.

The invention relates to the technical production field of metabolic engineering and genetic engineering, and particularly provides a uracil production strain as well as a construction method and application thereof. According to the strain, a uridine kinase gene udk is knocked out on an E.coli W3110 genome, and meanwhile, a T7RNA polymerase gene is integrated; the uridine monophosphate kinase gene pyrH is weakened; the method comprises the following steps: overexpressing a carbamyl phosphate synthetase gene carAB, a ribose phosphate pyrophosphate kinase gene prsA, a pyrimidine-5 '-nucleoside enzyme gene ppnN, UMP phosphohydrolase genes umpH and umpG, a ribonucleoside hydrolase 1 gene rihA and a glutamine synthetase gene glnA; an orotic acid nucleoside monophosphate decarboxylase gene pyrF and an orotic acid ribosyltransferase gene pyrE of wild type bacillus subtilis B.subtilis 168 are introduced in a heterologous manner, so that an orotate nucleoside monophosphate decarboxylase gene pyrF and an orotate ribosyltransferase gene pyrE are obtained. The safe, efficient and low-cost production of the uracil is realized.

The invention discloses a compound with a heteroaromatic ring sulfonamide structure as well as a pharmaceutical composition and application thereof. The invention provides a compound with a heteroaromatic ring sulfonamide structure as shown in a formula I, and pharmaceutically acceptable salts, stereoisomers, tautomers or isotope compounds thereof. The compound with the heteroaromatic ring sulfonamide structure is expected to be used for treating and / or preventing various diseases related to poly adenosine diphosphate ribose hydrolase (PARG). # imgabs0 #

The invention provides a uracil production strain and a construction method and application thereof.According to the strain, on an E.coli UR14 genome by means of a CRIPSR / Cas9 gene editing technology, firstly, psuG genes, preTA genes, rutA genes and upp genes are knocked out, so that decomposition of uracil is blocked; then, a uridine phosphorylase gene udp and a pyrimidine-5 '-nucleotide nucleotidase gene ppnN are subjected to overexpression, and synthesis and accumulation of uracil are synergistically enhanced; and finally, overexpression of the ribose phosphate mutase gene pgm further enhances the conversion of a by-product ribose phosphate 1-precursor 5-ribose phosphate 1-pyrophosphate and improves the carbon utilization rate, and the obtained strain has good genetic stability and high fermentation yield, can stably produce uracil, and has wide application prospects.

The present invention relates to solid forms of the poly(ADP-ribose) polymerase 7 (PARP7) inhibitor 5-[[(2S)-1-(3-oxo-3-[4-[5-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl]propoxy)propan-2-yl]amino]-4-(trifluoromethyl)-2,3-dihydropyridazin-3-one, and salts thereof, including methods of preparation thereof, where the inhibitor is useful in the treatment of cancer.

The invention belongs to the technical field of stem cell biological preparations, and particularly relates to an anti-aging compound preparation based on stem cells and application of the anti-aging compound preparation in delaying skin aging. The composition is composed of an inner water phase, a middle oil phase and an outer water phase, wherein the inner water phase is prepared from the following components: stem cell exosomes, hyaluronic acid, nicotinamide ribose, trehalose, mannitol, glycine and a citric acid buffer solution; the medium oil phase is prepared from the following components: medium chain triglyceride, shea butter, vitamin E succinate, PEG (Polyethylene Glycol) modified ceramide NP and cholesterol succinic acid monoester; the external water phase is prepared from the following components: polydatin, cellulose nanocrystals and an emulsifying agent. On the basis of a W / O / W emulsion system, a multi-layer anti-aging mechanism is constructed by utilizing a three-dimensional delivery framework of an inner water phase, an oil phase and an outer water phase and space-time synergy of active ingredients, the exosome permeation efficiency is improved through microneedle introduction, and the anti-oxidation and barrier repair effects are achieved by using multiple ingredients.

The invention relates to the technical production field of metabolic engineering and genetic engineering, and particularly provides a genetically engineered bacterium for producing 2 '-deoxyuridine as well as a construction method and application of the genetically engineered bacterium. According to the strain, deoxyuridine kinase tdk is knocked out on an E.coli W3110 genome, and T7 RNA polymerase is integrated; an aspartate transaminase gene aspC, a glutamine synthetase gene glnA, a 5 '-deoxynucleotidase gene yfbR and a uridine monophosphate kinase gene pyrH are subjected to overexpression; the method comprises the following steps: introducing a ribonucleoside diphosphate reductase gene nrdBCA from Escherichia phage T4 in a heterologous series connection manner; the CTP synthase gene pyrG * of Corynebacterium glutamicum is introduced in a heterologous mode, and the CTP synthase gene pyrG * of Corynebacterium glutamicum is introduced in a heterologous mode. The safe, efficient and low-cost production of the 2 '-deoxyuridine is realized.

Disclosed is a compound of formula (I), its pharmaceutically acceptable salt or pro-drug thereof, where R1, R2, X, L1, L2, L3, L4, L5, and R are as disclosed herein. The compounds disclosed herein can have poly[ADP-Ribose) polymerase 1 (PARP- 1) inhibitory activity. As such, the compounds and compositions containing the compounds, as disclosed herein, can have use for treatment of diseases associated with PARP-1.

The invention relates to the technical field of purification of nicotinamide ribose, in particular to a purification device and method for nicotinamide ribose, the purification device comprises a purification assembly, a filtering assembly is fixedly mounted at the lower end of the purification assembly, an adjusting assembly is fixedly mounted on the purification assembly, and the purification assembly comprises a purification barrel. A nicotinamide ribose feeding hole is fixedly formed in the purification barrel, a methanol feeding hole is fixedly formed in the upper end of the purification barrel, a motor is fixedly mounted at the upper end of the purification barrel, a stirring rod is fixedly mounted at the output end of the motor, and stirring blades are fixedly mounted on the stirring rod; the invention aims to cool and crystallize nicotinamide ribose through the purification assembly, drive the piston block I by independently pushing and pulling the piston rod I through the adjusting assembly, adjust the size of the feed opening I, change the cold air transmission rate and make the purification reaction more sufficient, and then filter nicotinamide ribose crystals through the filter assembly.

The invention discloses a genetically engineered bacterium for producing pseudouridine and a construction method of the genetically engineered bacterium, escherichia coli W3110 is used as a starting strain, the supply of precursor substances including aspartic acid, carbamyl phosphoric acid, glutamine and 5 '-phosphoribosyl pyrophosphate prpp is enhanced, pyrimidine nucleoside synthesis operon from bacillus subtilis is introduced, and the pseudouridine is produced. The invention discloses a pseudouridine-5 '-phosphosidase gene psuG and a preparation method thereof, and relates to the field of microorganisms, the field of genetic engineering and the field of fermentation engineering. The pseudouridine-5'-phosphosidase gene psuG is expressed by using high-copy plasmids, and the application of the pseudouridine-5 '-phosphosidase gene psuG to preparation of the pseudouridine-5'-phosphosidase gene psuG is provided. The strain is fermented in a 50L fermentation tank for 60h, the yield of pseudouridine reaches 50.8 g / L, the conversion rate is 18%, which is the highest value reported at present, and the strain has high industrial production value.

The present application provides polymorph of Ribociclib citrate salt and pharmaceutical compositions thereof. The present invention also relates to preparation method thereof. In particular, the invention relates to Ribociclib citrate dihydrate.

The present invention relates generally to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to methods for the use of calmodulin inhibitors and calcium channel blockers for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA).

The invention discloses temozolomide derivatives or pharmaceutically acceptable salts, crystal forms and solvates, wherein the structure of the temozolomide derivatives is shown as a formula I in the specification. According to the temozolomide derivative disclosed by the invention, damage caused by repairing temozolomide by cells is prevented by inhibiting PARP1 protein, so that the purpose of improving the overall anti-glioblastoma effect is achieved. The invention further discloses application of the temozolomide derivative or the pharmaceutically acceptable salt, the crystal form and the solvate to preparation of a PARP1 inhibitor. The invention also discloses application of the temozolomide derivative or the pharmaceutically acceptable salt, the crystal form and the solvate in preparation of medicines for preventing and / or treating tumors. The invention also discloses a pharmaceutical composition, and the pharmaceutical composition takes a safe and effective amount of temozolomide derivative or pharmaceutically acceptable salt, crystal form and solvate as effective components or main effective components, and is prepared into a pharmaceutically acceptable dosage form together with a pharmaceutically acceptable carrier.

The invention belongs to the technical field of biochemistry, and particularly relates to application of nicotinamide ribose malate in light aging resistance. The invention provides an application of nicotinamide ribose malate in light aging resistance, and particularly relates to an application of nicotinamide ribose malate in quantitative light aging resistance of human immortalized keratinocytes. According to the invention, 0.375 mg / mL to 1.50 mg / mL of nicotinamide ribose malate is used for resisting light aging of the skin, and the light aging resisting effect is improved by 12.13% to 35.09%. Particularly, 1.50 mg / mL of nicotinamide ribose malate is used for resisting light aging of human immortalized keratinocytes, the light aging resisting effect is improved by 35.09%, and the light aging resisting effect is obvious.

The invention relates to the technical field of glucose detection, and discloses a method for detecting glucose in d-ribose fermentation broth, which comprises the following steps: step 1, diluting a d-ribose fermentation broth sample and adjusting the d-ribose fermentation broth sample to a predetermined pH value to form a pretreated sample; 2, removing impurities and concentrating target components through solid-phase extraction to obtain a treated sample; 3, separating the sample by using high performance liquid chromatography, setting a mobile phase, a flow rate and a chromatographic column temperature, and separating to obtain a glucose component; and 4, injecting the separated components into a mass spectrum system on line, and detecting a characteristic ion signal of glucose. The high-sensitivity and accurate detection of glucose in the d-ribose fermentation liquor can be realized by adopting a high-performance liquid chromatography and mass spectrometry combined technology. Through optimized sample pretreatment and mobile phase selection, interference of other carbohydrates on glucose detection is reduced, and accurate determination of glucose concentration is ensured.

The present disclosure provides linker compounds of Formula (I) or (II):pharmaceutically acceptable salts thereof, and related scaffolds and conjugates. The present disclosure also relates to uses of the linker compounds, scaffolds, and conjugates, e.g., in delivering nucleic acid and / or treating or preventing diseases.

The invention discloses a method and application for enhancing cytidine production, and belongs to the field of genetic engineering and microbial engineering. The present invention knocks out cytidine deaminase gene cdd, uridine kinase gene udk, pyrimidine-specific ribonucleoside hydrolase gene rihB, nucleotide 5'-monophosphate nucleosidase gene ppnN, pyruvate oxidase gene poxB and integrates and expresses 5'-CTP diphosphohydrolase, orotate phosphoribosyltransferase, uridylate kinase mutant gene PyrH (R92G / D93G), as well as phosphoribosyl pyrophosphate synthetase gene prs, glucose-6-phosphate dehydrogenase gene zwf and 6-phosphogluconate dehydrogenase gene gnd, and constructs a recombinant Escherichia coli with enhanced cytidine synthesis ability, and the cytidine yield reaches 61.9g / L in a 30L fermenter without adding antibiotics and inducers, which can be used to realize the industrial production of cytidine and realize green biomanufacturing.

The invention relates to a process for producing a compound of the general formula Iworin, wherein R1 is selected at each occurrence from the group consisting of hydrogen, halogen, pseudohalogen and a group -O-R2, wherein R2 is selected at each occurrence from the group consisting of a substituted or unsubstituted, branched or unbranched alkyl group with 1 to 12 carbon atoms, a substituted or unsubstituted aryl group and a substituted or unsubstituted alkyl aryl group; m is 0 or an integer from 1 to 10; and n is 0 or 1 at each occurrence;with the proviso that at least one of the R1 substituents is a halogen or pseudohalogen and that at least one of the R1 substituents is a -O-R2 group. The process comprises the reaction of a compound of general formula II in which R6 is selected at each occurrence from the group consisting of hydrogen, a group R7 and a -O-R7 group, wherein R7 is selected at each occurrence from the group consisting of a substituted or unsubstituted, branched or unbranched alkyl group with 1 to 12 carbon atoms, a substituted or unsubstituted aryl group and a substituted or unsubstituted alkyl aryl group; m and n having the meanings given in connection with general formula I; with the proviso that at least one of the R6 substituents is a -O-R7 group;with a compound of general formula III, wherein R3 is selected at each occurrence from the group consisting of hydrogen, halogen, pseudohalogen and a residue R4; R4 is selected at each occurrence from the group consisting of a substituted or unsubstituted, branched or unbranched alkyl group with 1 to 12 carbon atoms, a substituted or unsubstituted aryl group and a substituted or unsubstituted alkylaryl group; x is 0 or 1; and y is 0 or 1 at each occurrence; provided that at least one of the residues R3 is a halogen or pseudohalogen; in the presence of a catalyst, wherein the catalyst is an organophosphine.

The invention discloses a screening method for a riboswitch capable of specifically recognizing doxycycline as well as rational transformation and application of the riboswitch, and belongs to the field of gene expression regulation and control. The invention provides a doxycycline specific riboswitch, establishes a high-throughput screening method based on a flow cytometry, and obtains the doxycycline riboswitch with further improved activation multiple by means of computer-aided prediction of binding sites of the riboswitch and calculation of mutation sites. According to a dose reaction curve, the riboswitch shows linear correlation at 40-100 [mu] g / L, and meanwhile, the constructed whole-cell sensor is low in price, high in stability and simple to operate, and can be used for on-site rapid detection.

Provided herein are nucleic acid inhibitors or activators that impact the expression, levels or activity of SNORA13 in a cell. Also provided are pharmaceutical compositions for using these activators and inhibitors for the treatment of ribosomopathies, cancer, and senescence-associated pathologies.

The invention discloses a rapid culture system of mycoplasma pneumoniae. The rapid culture system comprises a growth-promoting additive A, a growth-promoting additive B and a growth-promoting additive C, wherein the growth-promoting additive A is A549 cell lysis buffer; the growth promoting additive B is a mixture of deoxyribonucleoside triphosphate and / or ribonucleoside triphosphate. The rapid culture system can promote rapid growth and reproduction of the mycoplasma pneumoniae, fully meets the nutritional requirements and growth requirements of the mycoplasma pneumoniae, and is of great significance to isolated culture, enrichment culture, epidemic disease prevention and control and molecular diagnosis of the mycoplasma pneumoniae. The invention also provides a culture method of the mycoplasma pneumoniae. The invention also provides application of the rapid culture system of the mycoplasma pneumoniae in in-vitro cell culture of the mycoplasma pneumoniae.